Addex Therapeutics Reports Critical Going Concern Warning, Low Cash, and Material Internal Control Weakness in Annual Report
ADXN sits 26% above its 52-week low of $5.41 on light trading volume (0.1× avg).
Summary
Addex Therapeutics' annual report reveals a substantial doubt about its ability to continue as a going concern beyond mid-June 2026, driven by a significant net loss and critically low cash reserves, compounded by a material weakness in internal financial controls.
Key Events · Earnings and Guidance · ADXN
-
Going Concern Warning Issued
Independent auditors issued a going concern warning, stating that existing cash and cash equivalents are only sufficient to fund operations through mid-June 2026, raising substantial doubt about the company's future viability.
-
Significant Net Loss and Critically Low Cash
The company reported a net loss of CHF 6.7 million for the fiscal year 2025 and a critically low cash balance of CHF 1.6 million as of December 31, 2025.
-
Material Weakness in Internal Controls
Management concluded that internal control over financial reporting was not effective as of December 31, 2025, due to a material weakness identified during the preparation of financial statements.
-
Major Partnership Terminated
Janssen Pharmaceuticals terminated the ADX71149 development program and returned all related intellectual property to Addex on April 17, 2025.
Analysis · ADXN · Life Sciences
This annual report presents a dire financial outlook for Addex Therapeutics. The explicit "going concern" warning from the independent auditor, coupled with a very limited cash runway of just over a month, indicates an urgent need for significant capital. The substantial net loss for the year further highlights the company's cash burn. The termination of the Janssen partnership for ADX71149 removes a key development program and potential future revenue stream. Furthermore, the disclosure of a material weakness in internal financial controls is a serious governance issue that can erode investor confidence and complicate future financing efforts. While the company has initiated a new collaboration and restarted an ATM program, these are unlikely to fully offset the immediate and severe financial challenges.
At the time of this filing, ADXN was trading at $6.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $5.41 to $12.05. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.